Challenges in Implementing Clinical R&D Roadmap

To achieve Thailand 4.0 national plan Investigator perspective

Punnee Pitisuttithum Prof. Dr. Faculty of Tropical Medicine ,Mahidol University JITMM ,Dec 7, 2017;Bangkok

- Thailand 4.0 and related background
- Clinical R&D road map
- Challenges

Thailand 4.0, towards a value-based economy



Thailand 4.0 focuses on a "value-based economy," as the country needs to deal effectively with disparities and the imbalance between the environment and society.

Become a high-income nation

The first element aims to enhance the country's standing to become a high-income nation through developing it as a knowledge-based economy. With an emphasis on research and development, science and technology, creative thinking, and innovation.

Move toward an inclusive society

In the second element, Thailand will move toward an "inclusive society" with equitable access to the fruits of prosperity and development.

Focus on a sustainable growth and development

The third element focuses on "sustainable growth and development," in order to achieve economic growth and sustainable development without destroying the environment.



Thailand Science Technology and Innovation (STI) Landscape

 To revive Thailand's economic prosperity, the Thai Government has placed Science, Technology and Innovation (STI) on its national agenda as they are viewed as keys to move the country up the global value chain by establishing the National Research and Innovation Policy Council (NRIC).

Source: http://www.sti.or.th/



The National Research and Innovation Policy Council (NRIC)

- Is a single body to set the direction, policy and roadmap of research and innovation to facilitate national development.
- NRIC chaired by Prime Minister and Secretary-General of the National Research Council of Thailand (NRCT), and Secretary-General of the National Science Technology and Innovation Policy Office (STI Office) are the co-secretariat.

Source: http://www.sti.or.th/

Focus on Clinical Research Supporting Five Groups of Technology and Targeted Industries



Source: adopted from Thailand 4.0 Clir		linical Research Development and Targeted Industries		
(\mathbf{P})	Food & Agriculture - Biotech Become the center of premium agricultural products and food, and an exporter of technology in agriculture.	Genomics, Genotype-Phenotype- Microclimate Nutrition		
ţ.	Health & Wellness - Biomedical Build medical infrastructure and move Thailand forward to be "Medical Hub" of ASEAN within 2025.	Clinical research management service, Diagnosis and medical devices, well service and treatment innovation, innovative medicine, Thai herb.		
ß	Smart Devices & Robotics - Mechatronics Advance as a leader in automatic system, industrial robotics, and service robotics in ASEAN.	Healthcare & medical and service robotics, e.g., robots for elder care.		
	Digital, IOT and Embedded Technology: Enhance productivity, quality and innovation in various economic activities including agriculture, healthcare, and tourism.	Usage of digital technology to support healthcare industry, e.g., data analytics for research.		
Ø	Creativity, Culture and High-Value Services Synergize basic cultural assets, innovation and technology to become one of ASEAN's "Creative hubs" within the next ten years.	Clinical research to enhance innovation capability and support innovative ecosystem.		



Emphasis : Building up Infrastructure and Capabilities

Roadmap: Health & Wellness – Biomedical



Ref: http://www.samongthailand.com/thailand4-0/thailandevelopmentstrategy/


 Generic drug Biopharmaceutical Products - Biosimilar New technology Vaccine Diagnostic tests with economic potential Medical Devices, Robotics for handicapped Elderly Rehabilitation Centers Neutraceutical for health and beauty Medical Tourism New Biological Product for Cancer and Allergy New Biology Vaccine Diagnostic tests with economic potential Medical Robotics: comply with International Standard Guality reagents for automated diagnostic services Smart Village for Aging Digital Health Smart Village for Aging
Precision Medicine



Important Stakeholders :


Policy makers & Funders Industry partners, Scientists/Researchers/Investigators People/Society


Past and Present Capability in Vaccine R&D






Current situation: Number of clinical trials registered in www.clinicaltrial.gov







TOP INDICATIONS & TRIAL PHASES



13

CONFIDENTIAL





The number of Clinical Trials in Thailand by Phase from 2010 to 2015 Phase 1 Phase 2 Phase 3 Phase 4 Unknown Phase

Less phase I and phase II studies

Source: Clinical research impact study in Thailand report 2016, Deloitte Access Economics calculations


Number and Location of Independent Ethics Reviewers Accredited by TDFA across Thailand, 2016






There is limited collaboration between academia, government agencies and industries. More collaborative networks mainly mappen vertically within each stakeholder groups.


Source: Deloitte Access Economics








Proposed Five-year Strategic Clinical Research Roadmap



Source: Deloitte research and analysis





The Blue print : Health & Wellness – Biomedical (1)

คลัสเตอร์เทคโนโลยี (Cluster of Technology)	จุดตั้งต้นที่จะต้องริเริ่ม (Killer Applications)	ปัจจัยที่จะต้องเติมให้เต็ม (Missing Links)	กฎหมาย กฎระเบียบ ที่ต้องผ่อนปรน (Constrain Relaxation)
 Clinical Research Management Service Bio-engineering และ Bioprocess Engineering หุ่นยนต์ทางการแพทย์และ Biomedical Engineering Diagnosis และ Medical Devices Precision Medicine และ 	 Clinical Medicine, Clinical Research Center & Treatment และ Service Innovation Business Professional Contracted Research Organization (CRO) Drug, Biopharm, Neutraceuticals, Drug Dalizant, Taxisity Study 	 ประสิทธิภาพหน่วยงานใน การกำกับดูแลและรับรองเช่น องค์การเภสัชกรรม กรมวิทยาศาสตร์การแพทย์ อย. กรมทรัพย์สินทางปัญญา คณะกรรมการจริยธรรมการ วิจัยในมนุษย์กลาง (Central IRB) - ขาดความชัดเจนของ นโยบายในการรับรองจริยธรรมที่ เป็นแนวควมอียววัน 	 เพิ่มประสิทธิภาพ ลด ระยะเวลาการขอการรับรองหรือ รับบริการจากหน่วยงานในการ กำกับดูแลและรับรอง เช่น กรมวิทยาศาสตร์การแพทย์ อย. องค์การเภสัช กรมทรัพย์สินทาง ปัญญา, GLP PK lab เพิ่มการจัดซื้อจัดจ้างภาครัฐ จากผลงานวิจัยในประเทศ
Big Data • Wellness Service และ Treatment Innovation • Regenerative Medicine • สมุนไพรและการแพทย์แผน ไทย	Delivery, Toxicity Study, Bioequivalence และ Pharmacokinetics - ยาชีววัตถุ โดยเฉพาะอย่างยิ่ง Monoclonal Antibodies - Neutraceuticals สำหรับ สขภาพและความงาม	เป็นแนวทางเดียวกัน การเพิ่มจานวน Clinical Research Centers การเพิ่มจำนวนบุคลากร การสนับสนุน Translational Research 	 ISO Certified Testing (ควรใช้สถาบันต่างประเทศมา Certify) 4. ลดภาระงานสอนและ บริการของอาจารย์ใน มหาวิทยาลัยวิจัย



Blue Print : Health & Wellness – Biomedical (2)

คลัสเตอร์เทคโนโลยี (Cluster of Technology)	จุดตั้งต้นที่จะต้องริเริ่ม (Killer Applications)	ปัจจัยที่จะต้องเติมให้เต็ม (Missing Links)	กฎหมาย กฎระเบียบ ที่ต้องผ่อนปรน (Constrain Relaxation)
 Transborder Healthcare Nano Delivery Systems Chemical Synthesis / Extraction/ Modification Nutraceuticals เครื่องสำองค์ และสปา 	 ยาสำหรับรักษาโรคใหม่ๆอาทิ Dengue, Zika, Malaria อาหารสำหรับเด็กอ่อน ผู้สูงวัย และ Non-Communicable Diseases (NCDs) หุ่นยนต์ทางการแพทย์ Global Rehab Aging Robotics การฝึกอบรมทางการแพทย์ การวินิจฉัยและเคื่องมือทาง การแพทย์ Sleep – Monitor + Imaging 	 การเพิ่มจำนวน Knowledgeable Policy Maker การเพิ่มจำนวน Knowledgeable Regulatory Body การเพิ่มจำนวน CMO/CRO/Animal Testing การบริหารจัดการทรัพย์สิน ทางปัญญา IP ความเซี่ยวชาญใน Glycotechnology 	



Challenges: 1.Harmonizing Clinical Research Centers and Ethical Review Board

1. Establish National Enterprise for Clinical Research

• One stop-service and National CR drivers

CTMS, TCELS

CTMS Consortium of Thai Medical Schools **TCELS** Thailand Centre of Excellence of Life Sciences

Now-Mahidol University is a system integrater



Strategic Clinical Research Roadmap Strategy

 2. Streamline regulatory review process & timeline Faster regulatory review timeline 	 3. Align funding sources & improve allocation on More matching funds More oversea funding 	 4. Build research skills and capabilities More qualified researchers 	
CREC, FERCIT, NECAST, Thai FDA, MOPH	MRC, TRF, OHEC, HSRI, TCELS	National Enterprise, MOPH	
 CREC Central Research Ethics Committee FERCIT Forum of Ethical Review Committees in Thailand NECAST National Ethics Committee Accreditation System in Thailand MOPH Ministry of Public Health 	MRCMedical ResearchCouncilTRFTRFThe ThailandResearch FundOHECOHECOffice of HigherEducation CommissionHSRIHealth SystemsResearch InstituteTCELSThailand Centre ofExcellence of Life Sciences	MOPH Ministry of Public Health	

Strategic Clinical Research Roadmap Strategy MAHIDOL UNIVERSITY				
 5. Homogeneity, quality and standard of research facilities More qualified research facilities 	 6. Improve collaboration and expand CR network Strong CR network Outreach programs to oversea networks 	 7. Enhance digital data management and IT capabilities CR statistical database Protocol e- submission system 	 8. Improve public awareness & understanding Bigger patient population Collaboration in CR development 	Wisdom of the Land
DMSC, Thai FDA, MOPH	TCELS, HSRI, CTMS, ThaiTECT	NRCT, MOPH, National	MOPH, TCELS	
DMSC Department of Medical ScienceTCELS Thailand Centre of Excellence of LifeMOPH Ministry of Public HealthSciencesHSRI Health Systems Research InstituteHSRI Health Systems CTMS Consortium of Thai Medical Schools ThaiTECT Thailand towards Excellence in Clinical Trials		Enterprise, CTMS NRCT National Research Council of Thailand MOPH Ministry of Public Health CTMS Consortium of Thai Medical Schools	MOPH Ministry of Public Health TCELS Thailand Centre of Excellence of Life Sciences	



In Action : ESTABLISHING NCRC What's NEXT? (Perspective)

- Listing of potential CLINICAL SITES and GCP compliance sites
- Listing of potential bio pharmaceutical products including herbal products, prioritizing to get near success products with advancement criteria
- Issue of long term funding and commitments
- What's about LONG TERM PLAN?
 Long term plan from Bench to Bedside

2. Infrastructure and Capacity Building

One of the important pieces is Academia

Universities must spearhead the shift to 'Thailand 4.0' national March 01, 2017 01:00 By Nophakhun Limsamarnphun The Nation



To successfully implement the national modernization programme dubbed Thailand 4.0, the government needs to work closely with the private sector as well as educational institutes, since human resources are crucial to success.

Need for new curriculum/curricula



- More students go to Science, new methods of teaching
- More on research especially on clinical research
- More researchers works on translational work, and implementation
- More social scientists/researcher
- Career path and incentives
- More of phase I studies

Changing mindset/attitude towards PPPP Public, Private, People Partnership

MAHIDOL UNIVERSITY Wisdom of the Land

3.Collaborations & Clinical Research Network Capabilities

Location-based

Clinical research networks are formed based on location of resources and infrastructure.

Disease-based



Clinical research networks are formed to tackle specific therapeutic areas such as oncology, respiratory diseases, etc.

Capabilities of each CRC

Research Development

- Budget development and preparation
- Funding & grants
- Protocol development
- Contract negotiation

Project Management

- Feasibility study
- Site monitoring
- Communications with sponsor
- Budget management
- Sample management
- Study documentation development.

Marketing

PR and marketing with a national and global network.

Public Relations &

Regulatory Affair Joint IRB/EC

Public

Academics

Private

- submission and review
- Clinical research quality improvement

Data Management & Biostatistics

- Biorepository support

 Database of
 investigator and
- patient
- study database design and development
- Data collection and management
- Data analysis

Education and Training

- Clinical research training and education programs for clinicians, patients and caregivers
- Seminar and workshop

Tox/preclinical	COMPETENT AUTHORITIES- FDA,DMC,IP Departments	MAHID UNIVERSI Wisdom of th	
./nonclinical studies		ETHICS COMMITTEE	More dots/sites to be added
Biomedical product manufacturing under GMP	Sponsor/Funder //National CRC/CRO	Composition -Written opinion -Content of	
The medicinal	INVESTIGATOR	CLINICAL	China China China Bangkok Metropolitan Region: 11
product Information Monitoring	PATIENTS	LABORATORY ANALYSES	East: 1
	Community	-Equipment -Staff -Quality	(a) (b) South: 3



4. Knowledge Gaps on Basic Science: Novel Drug/vaccine/ risk markers and.....other aspects like

- 1. Identifying risk or prognostic factor which should be reproducible
- 2. If the measure is to be used as a diagnostic test, it should be sensitive and specific and have a high predictive value.

ETC

Need full time highly experienced scientists and researchers with qualified assistants especially in medical related fields& Multidisciplinary field

Through Effective Collaboration for an Impact of Global Health

- Collaboration among academia,
- government, private within the country.
- International collaboration is one of the
- important keysto fasten the development
- International source of funding as



ŕ

the country may not have sufficient resources especially on drugs/vaccine/diagnostics/monoclonal antibodies for neglected diseases



So we are running now : To achieve the goals within 1-5 Years

- Generic drug
- Biological Products Biosimilar
- Products from probiotics
- Herbs and Cosmetics
- Smart Medical and Devices Robotics for handicapped
- Elderly Rehab Centers
- Health and cosmetic products
- Medical Tourism





Health & Wellness – Biomedical



LOOKING FORWARD



Medical Hub of ASEAN in 2025



Thank you very much



Acknowledgement

CThaiTECT



Deloitte.

Academic Institutes Researchers , Scientists & Educators Ministry of Public Health Ministry of Science and Technology Ministry of Education Thai Government The people of Thailand